Neutrophils inhibit CD8+ T cells immune response by arginase-1 signaling in patients with sepsis

Xiao-kang Dai1 , Zhen-xing Ding1 , Yuan-yuan Tan1 , Hua-rui Bao1 , Dong-yao Wang2, 3, 4, Hong Zhang1

1 Department of Emergency, the First Affiliated Hospital of Anhui Medical University, Hefei 230027, China 2 Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, Hefei 230001, China

3 Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230001, China

4 Anhui Province Key Laboratory of Immunology in Chronic Diseases, Bengbu Medical College, Bengbu 233030, China

Corresponding Authors: Hong Zhang, Email: zhanghong20190628@163.com; Dong-yao Wang, Email: dywsn@ustc.edu.cn

BACKGROUND: Patients with sepsis often exhibit an acute inflammatory response, followed by an immunosuppressive phase with a poor immune response. However, the underlying mechanisms have not been fully elucidated.

METHODS: We sought to comprehensively characterize the transcriptional changes in neutrophils of patients with sepsis by transcriptome sequencing. Additionally, we conducted a series of experiments, including real-time quantitative polymerase chain reaction (RT-qPCR) and flow cytometry to investigate the role of arginase-1 signaling in sepsis.

RESULTS: Through the analysis of gene expression profiles, we identified that the negative regulation of T cell activation signaling was enriched, and the expression of arginase-1 was high in neutrophils from patients with sepsis. Furthermore, we conducted flow cytometry and found that the function of CD8⁺ T cells in septic patients was impaired. Moreover, neutrophils from septic patients inhibited the percentage of polyfunctional effector CD8⁺ T cells through arginase-1. Additionally, the proportions of granzyme B⁺IFN γ⁺CD8⁺ T and TNF α⁺IFN γ⁺CD8⁺ T cells increased after inhibition of arginase-1 signaling.

CONCLUSION: The impaired effector function of CD8⁺ T cells could be restored by blocking arginase-1 signaling in patients with sepsis.

KEYWORDS: Sepsis; Effector CD8⁺ T cells; Neutrophils; Arginase-1; Interferon-γ

World J Emerg Med 2022;13(4):266–273 DOI: 10.5847/wjem.j.1920-8642.2022.068

INTRODUCTION

Sepsis is a life-threatening organ dysfunction mainly caused by an abnormal infection-induced immune response.[1-4] In the excessive inflammatory response stage of sepsis, the immune response to sepsis may further cause cell and tissue injury or multiple organ dysfunction syndrome (MODS) with high morbidity and mortality.^[5-7] In recent years, the incidence rate of sepsis has increased worldwide.^[8,9] More attention has been given to the description of unique biological phenotypes in patients with sepsis; $[10,11]$ however, the mechanisms underlying sepsis have not been fully elucidated.

Neutrophils play an important role in the innate immune system.^[11] Although neutrophils survive for only several hours, they contribute to eradicating microorganisms and the survival of patients with sepsis. Neutrophils can effectively clear extracellular microorganisms mainly through direct phagocytosis.[12,13] Recent studies suggested that neutrophils can also clear pathogens through neutrophil extracellular traps (NETs). $[14,15]$ In sepsis, the

phenotype and function of circulatory neutrophils can be altered significantly.^[16] In early sepsis, neutrophils can migrate from the bone marrow to peripheral blood, and the level of neutrophils can increase by ten-fold within several hours compared to healthy controls.^[17]

Sepsis is always accompanied by an impaired immune response mediated by immunosuppressive mechanisms, including the expansion of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and the production of suppressive factors, including arginase-1 $(ARG1).$ ^[1,18] Sepsis can expand a CD39⁺ plasmablast population and promote immunosuppression through adenosine-mediated inhibition of macrophage antimicrobial activity.^[19] During sepsis, the level of plasma arginase is elevated. Human neutrophils also express a high level of ARG1, which can deplete arginine from the surrounding medium, suppressing the production of nitric oxide (NO) and impeding the clearance of pathogens.[20,21] In addition, the release of ARG1 from neutrophils has been associated with T cells dysfunction in various pathologies.^[20,22]

This study provides insight into the dysfunction of CD8+ T cells in patients with sepsis. Herein, we evaluated the transcriptional profiles and the expression of ARG1 in neutrophils from septic patients and compared them with those of healthy controls. Moreover, we aimed to ascertain whether targeting ARG1 can be a promising approach for restoring the functions of $CDS⁺ T$ cells in patients with sepsis.

METHODS

Isolation of samples, CD8+ T cells, and neutrophils

Peripheral-blood mononuclear cells (PBMCs) were isolated by ficoll density gradients from patients with sepsis and healthy controls (Table 1 and Supplementary Figure 1), and resuspended in RPMI 1640 complete medium (10% fetal calf serum, and 1% streptomycin/ penicillin). CD8⁺ T cells were purified from PBMCs of healthy controls by a magnetic-activated cell sorter (MACS) kit (Miltenyi Biotec, Germany). CD14- CD15⁺ CD16⁺ neutrophils were sorted by FACS Aria (BD Bioscience, USA) from PBMCs of patients with sepsis.

Ex vivo **flow cytometry experiments**

CD8⁺ T cells were cocultured with neutrophils and stimulated overnight with or without arginase inhibitor 1 (10 μmol/L; MedChemExpress, USA). Cells were stained with human monoclonal antibodies (as described in Supplementary Table 1). Before staining with

antibodies, mouse serum was used to block the binding of nonspecific Fc-receptors. Next, intracellular staining of cytokines was performed with 4 h of stimulation with ionomycin (1 μg/mL; Calbiochem, Germany), phorbol 12-myristate 13-acetate (PMA) (50 ng/mL; Sigma, Germany) and monensin (10 μg/mL; Sigma, Germany). Anti-CD107a was added at the same time for 4 h. Cells were then collected and stained for surface or intracellular markers using antibodies (BD Biosciences, USA) according to the manufacturer's instructions. Data were collected using the FCM LSR II flow cytometer (BD Biosciences, USA) and analyzed with FlowJo software (Tree Star, USA).

Transcriptome sequencing and analyses of gene expression

 $CD14^{\circ}CD15^{\circ}CD16^{\circ}$ neutrophils were isolated from PBMCs of patients with sepsis and healthy controls for transcriptome sequencing using the BGISEG platform (Beijing Genomics Institution). The heat map of differentially expressed genes (DEGs) was analyzed with MEV v4.8.1. DEGs were defined as those with a fold change ≥ 2.0 in the expression between two groups and signal values higher than background signals. An adjusted *P*-value was used to determine DEGs. Next, to obtain insights into the change in phenotype, enrichment analyses of DEGs were performed using the Kyoto Encyclopedia of Genes and Genomes (KEGG, [www.](http://www.kegg.jp/) [kegg.jp/\)](http://www.kegg.jp/) databases and Gene Ontology (GO, [www.](http://www.geneontology.org/) [geneontology.org/](http://www.geneontology.org/) $)$.^[23] Raw RNA-seq data have been deposited in the Gene Expression Omnibus Repository of the National Center for Biotechnology Information (accession number: GSE186054).

For gene expression analyses, total RNA was isolated using TRIzol reagent (Invitrogen, USA), and cDNA synthesis was performed using M-MLV Reverse Transcriptase (Invitrogen, USA) and random primers according to manufacturer's instructions.[23] qRT-PCR was carried out using SYBR Premix Ex Taq (TaKaRa, Japan). Primers are listed in Supplementary Table 2.

Statistical analysis

GraphPad Prism 8 software were employed to perform statistical analysis. We used two-tailed unpaired or paired Student's *t*-tests between two groups or oneway analysis of variance (ANOVA) across multiple groups. Data were presented as mean \pm standard deviation. A *P*-value<0.05 was considered statistically significant.

RESULTS

Transcriptional profiles of neutrophils from septic patients

When diagnosed with sepsis, the number of neutrophils was significantly increased in blood (Table 1). Neutrophils can inhibit the effector function and activation of T cells.^[14,24,25] Insufficient T cells activation was associated with an inability to recognize pathogens properly. To gain further mechanistic insights, we isolated neutrophils from patients with sepsis and healthy controls for whole-genome transcriptome analyses by microarrays (Figure 1A). The transcriptional profiles of neutrophils from patients with sepsis differed from those of healthy controls. A total of 2,365 genes exhibited upregulated expression, and 1,354 genes showed downregulated expression in septic patients compared with healthy controls (Figure 1B). Enrichment analyses using the GO database revealed varying immunological processes, including negative regulation of T cell activation (Figure 1C). By comparing septic patients with healthy controls, we found that acute inflammatory response signaling and negative regulation of T cell

Figure 1. The transcriptional profiles of neutrophils from patients with sepsis differed from those of healthy controls. A: the protocol of isolation of neutrophils from healthy controls (*n*=3) and patients with sepsis (*n*=3); B: the top-200 genes with differential expression (fold change greater than two-fold) in neutrophils from patients with sepsis compared with those in healthy controls were selected for heat map analyses; each column depicts one sample; C: enrichment analyses of differentially expressed genes were performed (using the Gene Ontology database) to evaluate enriched biological processes between neutrophils from patients with sepsis and healthy controls; enrichment of regulation of negative regulation of T cell activation-related biological processes was included.

Table 1. Characteristics of sepsis patients and healthy controls

Characteristic	Healthy controls $(n=10)$	Sepsis patients $(n=10)$
Gender (M/F)	5/5	6/4
Age, years	$27(19-43)$	$31(23-42)$
White blood cell count, $\times 10^{9}$ /L 5.05 (4.07–7.46)		$9.46(6.78-21.30)$
C-reactive protein, mg/L	$2.07(1.44 - 3.56)$	98.30 (70.70–133.50)
Procalcitonin, ng/mL	$0.11(0.03 - 0.25)$	46.60 (21.70–54.50)
Neutrophil count, $\times 10^9$ /L	$3.64(1.25 - 7.11)$	23.74 (15.60-36.70)
Lymphocyte count, $\times 10^{9}/L$	$1.84(0.76-2.60)$	$0.53(0.32 - 1.51)$
Monocyte count, $\times 10^{9}/L$	$0.48(0.38 - 0.71)$	$0.66(0.39-1.21)$
SOFA score	0	$6.35(3.00-9.00)$
Infection with Klebsiella pneumoniae	8	8
Infection with Staphylococcus aureus	\mathfrak{D}	2

Variables are expressed as mdian (interquartile range) or number. M: male; F: female;SOFA: sequential organ failure assessment.

activation signaling were enriched in neutrophils from patients with sepsis (Figure 1C). In general, our data demonstrated differences in transcriptional profiles in neutrophils from patients with sepsis and healthy controls. Specifically, neutrophils from septic patients mainly showed the characteristics of negative regulation of T cell activation.

Increased expression of *ARG1* **in neutrophils**

Human neutrophils express high amounts of *ARG1*, which could significantly downregulate T-cell activation.^[18] To determine whether there was an increase in the expression of *ARG1* in the neutrophils of patients with sepsis, we first performed DEGs analysis and gene set enrichment analysis (GSEA). Meanwhile, we found an increase in the expression of DEGs related to the negative regulation of T cells activation in neutrophils of patients with sepsis compared with that in neutrophils of healthy controls (Figure 2). Of these, there was an 82-fold increase in ARG1 expression (Figure 2A), implying its significant role in regulating the activation of T cells. These results demonstrated the impaired activation of T cells in the sepsis microenvironment. To determine the expression of ARG1 and some other immunosuppressive-related genes such as *IL-10*, which has long been described as one of the mediators of sepsis-induced immunosuppression,^[26-29] we purified neutrophils from patients with sepsis and healthy controls to carry out PCR. Notably, the expression of *ARG1* was increased in the neutrophils of septic patients (Figures 2A and 3A-D). The expression of *ARG1* in neutrophils from healthy controls was low (Figures

2A and 3A-D). This difference in expression was also confirmed using flow cytometry (Figure 3E). These data suggested that in neutrophils from patients with sepsis, *ARG1* expression was significantly upregulated.

Neutrophils inhibited CD8+ T cells immune response by ARG1 signaling *ex vivo*

To further demonstrate that inhibition of ARG1 signaling could restore the effector function of CD8+ T cells of septic patients, we first processed the neutrophils from septic patients with arginase inhibitor 1. The expression of ARG1 was decreased (Figure 4A). Next, we purified CD8⁺ T cells from PBMCs of healthy controls and neutrophils from patients with sepsis (Figure 4B). After CDS^+ T cells were cocultured with

Figure 2. Differentially expressed genes (DEGs) analysis and gene set enrichment analysis (GSEA) of neutrophils. A: heat map of negative regulation of T cell activation-related genes with differential expression in neutrophils from patients with sepsis compared with those from healthy controls; B: GSEA revealed an increase in negative regulation of T cell activation processes in neutrophils from patients with sepsis compared with that in healthy controls. NES: normalized enrichment score; FDR: false discovery rate.

neutrophils from septic patients, the percentage of IFN-γ and $TNF-\alpha$ were coexpression. In addition, granzyme B and CD107a were coexpression, as well as IFN-γ and granzyme B coexpression by CDS^+ T cells were significantly decreased. However, after being treated with arginase inhibitor 1, the percentage of IFN- γ and TNF- α coexpression and IFN-γ and granzyme B coexpression by CD8⁺ T cells were significantly restored (Supplementary Figure 2; Figure 4C and D). Importantly, we found that the polyfunctional effector $CD8⁺$ T cells were significantly decreased in septic patients compared with that of healthy controls (Figures 4C and D). In general, these findings suggested that the immune response of CD8⁺ T cells from septic patients was impaired, and the inhibition of ARG1 signaling may be related to the recovery of effector function of CD8⁺ T cells.

DISCUSSION

Our current study provided direct evidence that the expression of ARG1 in the neutrophils of septic patients was high. Moreover, we demonstrated that ARG1 inhibition significantly restored the effector function of

CD8⁺ T cells. In summary, our results provided three main insights into the underlying mechanisms and potential for sepsis therapy.

First, to elucidate the immunological characteristics of septic patients, we performed routine laboratory tests. Consistent with the results of other studies, we found that the number of neutrophils was significantly increased,[16,30-32] while the lymphocytes were decreased in septic patients. To investigate the difference in neutrophils between septic patients and healthy controls, we performed RNA-seq analysis and found that the transcriptional profiles of the neutrophils differed between the two groups. Additionally, we verified that negative regulation of T cell activation signaling was enriched in neutrophils from patients with sepsis. Furthermore, we observed high expression of several immunosuppressive indicators, such as IL-10 and ARG1 in neutrophils from septic patients.

Next, to confirm that ARG1 expression was high in neutrophils from septic patients, we performed qRT-PCR and flow cytometry. The expression of ARG1 was significantly increased in neutrophils from patients with sepsis. CD8⁺ T cells play important roles in the host

Figure 3. Neutrophils expression of arginase-1 in patients with sepsis. A-D: *ARG1*, *IL-10*, *PAG1*, and *RUNX1* expression in neutrophils from patients with sepsis and healthy controls, as assessed by qRT-PCR. Data were representative of six experiments; E: representative histograms (left) and percentage statistics (right) calculated for the expression of arginase-1 in neutrophils of patients with sepsis (red; $n = 6$) and healthy controls (blue; *n* = 6). Data were analyzed by two-tailed unpaired Student's *t*-test; data were presented as mean ± standard deviation.

Figure 4. Inhibition of arginase-1 signaling elevates the percentage of polyfunctional effector CD8⁺ T cells. A: representative histograms showing the analysis of arginase-1 expression in neutrophils of two patients with sepsis after being treated with arginase inhibitor 1; B: the protocol of the isolation of CD8⁺ T cells from patients with sepsis and healthy controls; and CD14⁻CD15⁺CD16⁺ neutrophils from patients with sepsis. Purified $CD8^+$ T cells from healthy controls were cocultured with neutrophils (ratio = 3:1), treated with or without arginase inhibitor 1 (10 µmol/L); C and D: PBMCs of septic patients (red), or CD8⁺T cells purified from healthy controls and cocultured with neutrophils, and treated with (blue) or without (purple) arginase inhibitor 1 (10 µmol/L) overnight, or PBMCs of healthy controls (black), were stimulated with PMA for 4 h. CD8⁺ T cells were gated for analysis. Representative flow cytometry plots (C) and pool data (D) of the proportion of IFN-γ and granzyme B coexpression, IFN-γ and TNF-α coexpression, IFN-γ and CD107a coexpression, as well as CD107a and granzyme B coexpression by CD8⁺ T cells. n 6. For (D), data were analyzed by one-way ANOVA with Tukey's multiple comparisons test; Data are presented as mean ± standard deviation.

defense against infections.[33-36] However, in patients with sepsis, the immune response of $CDS⁺ T$ cells was impaired. As ARG1 was reported to be associated with T-cell dysfunction in several pathologies,[18,20,22] we considered whether inhibition of ARG1 would contribute to restoring the function of $CD8⁺$ T cells.

Third, consistent with expectations, we demonstrated that the effector function of $CDS⁺ T$ cells was impaired in septic patients. Furthermore, after coculturing with neutrophils from septic patients, the immune response of CD8+ T cells from healthy controls decreased significantly. Additionally, arginase inhibitor 1 led to the marked restoration of immune function of CD8⁺ T cells *ex vivo*. However, several important questions remain to be answered, including the challenges of developing and using new model systems. Furthermore, we did not clarify other mechanisms that could lead to sepsis and the dysfunction of CD8+ T cells. We also did not explain how ARG1 obstructs the function of $CDS⁺ T$ cells in sepsis.

CONCLUSION

Our results reveal the transcriptional profile features of patients with sepsis and indicate that inhibition of ARG1 might help relieve sepsis.

Funding: This work was supported by the Research Fund for the Key Laboratory of Anhui Province (KLICD-2022-Z2), the Scientific Research Fund of Anhui Medical University (2011×kj083) and the Scientific Research Fund of the First People's Hospital of Hefei (201642).

Ethical approval: The studies were approved by the local Ethics Board of the First Affiliated Hospital of Anhui Medical University (No. PJ2019-06-09). Experiments were conducted in accordance with the ethical guidelines of the 1975 *Declaration of Helsinki*, the Principles of Good Clinical Practice, and the guidelines of China's regulatory requirements. Each participant provided written informed consent.

Conflicts of interest: The authors have declared no conflict of interest.

Contributors: All authors have read and approved the article. XKD designed and performed the experiments, analyzed and interpreted the data. ZXD, YYT and HRB helped to perform the experiments, collected samples and information from patients. HZ and DYW supervised the project, provided strategic planning, and interpreted some data. XKD wrote the manuscript with HZ.

All the supplementary files in this paper are available at http:// wjem.com.cn.

REFERENCES

1 Chen J, Wei HM. Immune intervention in sepsis. Front Pharmacol. 2021;12: 718089.

-
- 2 Prescott HC, Angus DC. Enhancing recovery from sepsis: a review. JAMA. 2018;319(1): 62-75.
- 3 van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17(7): 407-20.
- 4 Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 2016;353: i1585.
- 5 Spinella PC, Tucci M, Fergusson DA, Lacroix J, Hébert PC, Leteurtre S, et al. Effect of fresh vs standard-issue red blood cell transfusions on multiple organ dysfunction syndrome in critically ill pediatric patients: a randomized clinical trial. JAMA. 2019;322(22): 2179-90.
- 6 Rhee SG. Overview on peroxiredoxin. Mol Cells. 2016;39(1): 1-5.
- 7 Huang M, Cai SL, Su JQ. The pathogenesis of sepsis and potential therapeutic targets. Int J Mol Sci. 2019;20(21): 5376.
- 8 Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193(3): 259-72.
- 9 Zhang H, Zeng L, Xie M, Liu J, Zhou BR, Wu RL, et al. TMEM173 drives lethal coagulation in sepsis. Cell Host Microbe. 2020;27(4): 556-70.e6.
- 10 Karakike E, Giamarellos-Bourboulis EJ. Macrophage activationlike syndrome: a distinct entity leading to early death in sepsis. Front Immunol. 2019;10: 55.
- 11 Liu L, Sun BW. Neutrophil pyroptosis: new perspectives on Sepsis. Cell Mol Life Sci. 2019;76(11): 2031-42.
- 12 Group RC, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, et al. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020;383(21): 2030-40.
- 13 Castanheira FVS, Kubes P. Neutrophils and NETs in modulating acute and chronic inflammation. Blood. 2019;133(20): 2178-85.
- 14 Dąbrowska D, Jabłońska E, Garley M, Ratajczak-Wrona W, Iwaniuk A. New aspects of the biology of neutrophil extracellular traps. Scand J Immunol. 2016;84(6): 317-22.
- 15 Yamamoto K, Yamada H, Wakana N, Kikai M, Terada K, Wada N, et al. Augmented neutrophil extracellular traps formation promotes atherosclerosis development in socially defeated apoE−/− mice. Biochem Biophys Res Commun. 2018;500(2): 490-6.
- 16 Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. 2017;16(1): 137.
- 17 Manz MG, Boettcher S. Emergency granulopoiesis. Nat Rev Immunol. 2014;14(5): 302-14.
- 18 Sippel TR, Shimizu T, Strnad F, Traystman RJ, Herson PS, Waziri A. Arginase I release from activated neutrophils induces peripheral immunosuppression in a murine model of stroke. J Cereb Blood Flow Metab. 2015;35(10): 1657-63.
- 19 Nascimento DC, Viacava PR, Ferreira RG, Damaceno MA, Piñeros AR, Melo PH, et al. Sepsis expands a CD39⁺ plasmablast population that promotes immunosuppression via adenosinemediated inhibition of macrophage antimicrobial activity. Immunity. 2021;54(9): 2024-41.e8.
- 20 Darcy CJ, Woodberry T, Davis JS, Piera KA, McNeil YR, Chen YW, et al. Increased plasma arginase activity in human sepsis: association with increased circulating neutrophils. Clin Chem Lab Med. 2014;52(4): 573-81.
- 21 Reizine F, Lesouhaitier M, Gregoire M, Pinceaux K, Gacouin

A, Maamar A, et al. SARS-CoV-2-induced ARDS associates with MDSC expansion, lymphocyte dysfunction, and arginine shortage. J Clin Immunol. 2021;41(3): 515-25.

- 22 Pang R, Zhou H, Huang YF, Su YB, Chen XH. Inhibition of host arginase activity against staphylococcal bloodstream infection by different metabolites. Front Immunol. 2020;11: 1639.
- 23 Cong JJ, Wang XW, Zheng XH, Wang D, Fu BQ, Sun R, et al. Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression. Cell Metab. 2018;28(2): 243-55.e5.
- 24 Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019;50(4): 924-40.
- 25 Lee KH, Kronbichler A, Park DDY, Park Y, Moon H, Kim H, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. Autoimmun Rev. 2017;16(11): 1160- 73.
- 26 Bergmann CB, Salyer CE, Beckmann N, Caldwell CC. Intraperitoneal neutrophil IL-10 production is promoted by interferon γ in a murine model of sepsis model in the acute phase of sepsis. Biochem Biophys Res Commun. 2020;530(1): 278-84.
- 27 Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, Standiford TJ. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol. 1999;162(1): 392-9.
- 28 Fu BQ, Wang DY, Shen XK, Guo C, Liu YY, Ye Y, et al. Immunomodulation induced during interferon-α therapy impairs the anti-HBV immune response through $CD24^+$ CD38^{hi} B cells. Front Immunol. 2020;11: 591269.
- 29 Wang DY, Zheng XH, Fu BQ, Nian ZG, Qian YB, Sun R, et al.

Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling. EBioMedicine. 2019;46: 119-32.

- 30 Park I, Kim M, Choe K, Song E, Seo H, Hwang Y, et al. Neutrophils disturb pulmonary microcirculation in Sepsisinduced acute lung injury. Eur Respir J. 2019;53(3): 1800786.
- 31 Mortaz E, Alipoor SD, Adcock IM, Mumby S, Koenderman L. Update on neutrophil function in severe inflammation. Front Immunol. 2018;9: 2171.
- 32 Seree-Aphinan C, Vichitkunakorn P, Navakanitworakul R, Khwannimit B. Distinguishing sepsis from infection by neutrophil dysfunction: a promising role of CXCR2 surface level. Front Immunol. 2020;11: 608696.
- 33 Shen XK, Fu BQ, Liu YY, Guo C, Ye Y, Sun R, et al. NKp30⁺ NK cells are associated with HBV control during pegylatedinterferon-alpha-2b therapy of chronic hepatitis B. Sci Rep. 2016;6: 38778.
- 34 Kurachi M. CD8⁺ T cell exhaustion. Semin Immunopathol. 2019;41(3): 327-37.
- 35 Kumar BV, Connors TJ, Farber DL. Human T cell development, localization, and function throughout life. Immunity. 2018;48(2): 202-13.
- 36 Shen XF, Cao K, Jiang JP, Guan WX, Du JF. Neutrophil dysregulation during sepsis: an overview and update. J Cell Mol Med. 2017;21(9): 1687-97.

Received November 02, 2021 Accepted after revision February 24, 2022